当前制药行业竞争激烈,药企面临着诸多挑战。如何实现业绩的持续增长,成为了各大药企亟待解决的问题。2024 年,辉瑞凭借外延式扩张战略实现总营收 636.27 亿美元,在全球制药巨头中排名第一(按制药业务),重新夺回了“宇宙第一大药厂”的宝座。然而,辉瑞股价却一直跌跌不休,截至 6 月 17 日收盘,总市值达 1364.49 亿美元,市盈率(TTM)为 17.31 倍。反过来,营收规模不及辉瑞的礼来...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.